Discovery of MK-2118, a Small-Molecule Agonist of STING
Timothy Henderson, Michael D. Altman, Alexei V. Buevich, Brandon Cash et autres
0 citationsACS Medicinal Chemistry Letters
Samanthi A. Perera
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
124Publications signalées
5609Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Heat shock proteins researchCancer Immunotherapy and BiomarkersCytokine Signaling Pathways and InteractionsATP Synthase and ATPases Researchinterferon and immune responses
Publications récentes
Table 3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Figure 3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Supplemental Table S6 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Supplemental Figure S1 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Supplemental Figure S2 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Table 2 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Table 1 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Supplemental Table S2 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Supplemental Figure S4 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Supplemental Table S7 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
Supplemental Table S3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.